Corcept director plans sale of 30,000 shares

Corcept Therapeutics Inc. (CORT) insider James N. Wilson filed a Rule 144 notice indicating an intention to sell up to 30,000 shares of common stock, to be sold through The Charles Schwab Corporation, with an aggregate market value of $3,344,400.

Rhea-AI Filing Summary

Corcept Therapeutics Inc. (CORT) insider James N. Wilson filed a Rule 144 notice indicating an intention to sell up to 30,000 shares of common stock, to be sold through The Charles Schwab Corporation, with an aggregate market value of $3,344,400. The shares relate to stock option awards dated February 24, 2026. Wilson also reported prior sales of 10,000 shares for $882,986 on July 15, 2026 and 10,000 shares for $1,114,261 on August 14, 2026.

Key Figures

Shares to be sold: 30,000 shares Aggregate market value of planned sale: $3,344,400 Shares sold July 15, 2026: 10,000 shares +3 more

6 metrics

Shares to be sold 30,000 shares Common stock James N. Wilson intends to sell under Rule 144

Aggregate market value of planned sale $3,344,400 Value associated with 30,000 Corcept shares to be sold

Shares sold July 15, 2026 10,000 shares Common stock sold for $882,986 in the prior three months

Proceeds July 15, 2026 sale $882,986 Sale of 10,000 Corcept shares on July 15, 2026

Shares sold August 14, 2026 10,000 shares Common stock sold for $1,114,261 in the prior three months

Proceeds August 14, 2026 sale $1,114,261 Sale of 10,000 Corcept shares on August 14, 2026

Key Terms

Rule 144, stock option awards, Form 144

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option awards financial

"COMMON | 02/24/2026 | STOCK OPTION AWARDS | ISSUER"

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Corcept Therapeutics (CORT)?

The filing discloses that director James N. Wilson intends to sell up to 30,000 shares of Corcept Therapeutics common stock under Rule 144, with an indicated aggregate market value of $3,344,400, through The Charles Schwab Corporation.

How many Corcept Therapeutics (CORT) shares is James N. Wilson planning to sell?

James N. Wilson plans to sell up to 30,000 shares of Corcept Therapeutics common stock, as stated in the Form 144 notice, with the securities to be sold on or after February 24, 2026 and related to stock option awards.

What is the aggregate market value of the CORT shares to be sold under this Form 144?

The Form 144 lists an aggregate market value of $3,344,400 for the 30,000 shares of Corcept Therapeutics common stock that James N. Wilson intends to sell through The Charles Schwab Corporation.

What Corcept Therapeutics (CORT) share sales has James N. Wilson made in the past three months?

In the past three months, James N. Wilson sold 10,000 shares of CORT for $882,986 on July 15, 2026 and another 10,000 shares for $1,114,261 on August 14, 2026, as reported in the Form 144.

What is the source of the Corcept Therapeutics (CORT) shares being sold by James N. Wilson?

The Form 144 states that the 30,000 shares of Corcept Therapeutics common stock to be sold by James N. Wilson are related to stock option awards from the issuer, with a transaction date of February 24, 2026.

Through which broker will the planned Corcept Therapeutics (CORT) share sale occur?

The notice identifies The Charles Schwab Corporation, located in Westlake, Texas, as the broker through which the 30,000 shares of Corcept Therapeutics common stock are intended to be sold under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 10:24 AM Accepted by SEC EDGAR 09/15/2026 - 10:23 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001236387
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INC
SEC File Number	000-50679
Address of Issuer	101 REDWOOD SHORES PARKWAY REDWOOD CITY CALIFORNIA 94065
Phone	650.688.8803
Name of Person for Whose Account the Securities are To Be Sold	WILSON JAMES N
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	THE CHARLES SCHWAB CORPORATION 3000 Schwab Way Westlake TX 76262	30000	3344400.00	108098397	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	02/24/2026	STOCK OPTION AWARDS	ISSUER			30000	02/24/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JAMES WILSON 101 Redwood Shores Parkway Redwood CA 94065	COMMON	07/15/2026	10000	882986.00
JAMES WILSON 101 Redwood Shores Parkway Redwood CA 94065	COMMON	08/14/2026	10000	1114261.00

144: Remarks and Signature

Remarks	FULL ACCT TITLE: JAMES N & PAMELA WILSON TRUST, P WILSON & J WILSON TTEE
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	JAMES WILSON
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)